AIMDW

Ainos, Inc. operates as a clinical-stage biopharmaceutical company focused on developing treatments for viral infections and cancer. Headquartered in San Diego, California, the company advances therapeutic candidates through its proprietary drug development platform. Ainos's pipeline centers on AIV001, an investigational therapy for chronic hepatitis B virus (HBV) infection, which represents its lead clinical program. The company also develops AIV002 for cancer immunotherapy applications. Ainos conducts research and development activities aimed at addressing unmet medical needs in infectious diseases and oncology, with particular emphasis on liver-related conditions. The company operates with a lean organizational structure typical of early-stage biotechnology firms, concentrating resources on clinical trials and regulatory pathways. In recent years, Ainos has focused on advancing its HBV program through clinical milestones and has engaged in strategic partnerships to support development activities. The company maintains intellectual property rights covering its therapeutic candidates and underlying technologies. As a clinical-stage entity, Ainos does not currently generate product revenue and funds operations through equity financings and potential collaboration agreements. The company's stock trades on the NASDAQ Capital Market under the ticker symbol AIMD, providing public market access for investors interested in early-stage biopharmaceutical development opportunities focused on viral hepatitis and immuno-oncology indications.